Pelacarsen

1. Pelacarsen decreases lipoprotein in humans (up to 99%).

   Review

   Targeting Lipoprotein(a): A New Era in Cardiovascular Disease Prevention · Methodist DeBakey cardiovascular journal · 15 Sep 2026

2. Pelacarsen decreases lipoprotein in humans (up to 80-95% reductions).

   Review

   Lipoprotein(a) in Japan: An Expert Consensus Statement · Journal of atherosclerosis and thrombosis · 13 Sep 2026

3. Pelacarsen decreases lipoprotein in humans (up to 80%).

   Review

   Lipoprotein(a): Cardiovascular Risk and Emerging Targeted Therapies · American journal of cardiovascular drugs : drugs, devices, and other interventions · 31 Aug 2026

4. Pelacarsen decreases lipoprotein in humans (Up to 80% reduction).

   Reviewantisense oligonucleotide

   Efficacy and tolerability of targeted lipoprotein(a)-lowering therapies: A systematic review · Journal of clinical lipidology · 26 Aug 2026

Lipoprotein →

1. Pelacarsen has no effect on primary composite endpoint in humans.

   Reviewpatients with established atherosclerotic cardiovascular disease and lipoprotein(a) of at least 70 mg/dLn = 8,323

   The Lipoprotein(a) Paradox: From Vulnerable Plaque to a Missed Endpoint · Preprints.org · 15 Sep 2026 · Preprint